Prosecution Insights
Last updated: November 04, 2026
Application No. 18/682,062

METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN

Non-Final OA §101§112
Filed
Feb 07, 2024
Priority
Aug 17, 2021 — CN 202110943248.1 +1 more
Examiner
WITHERSPOON, SIKARL A
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mabwell (Shanghai) Bioscience Co. Ltd.
OA Round
1 (Non-Final)
86%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allowance Rate
1439 granted / 1668 resolved
+26.3% vs TC avg
Minimal -20% lift
Without
With
+-20.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
41 currently pending
Career history
1714
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
45.9%
+5.9% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
17.3%
-22.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1668 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 4, 6, 9, 12, 14, and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 2 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, an fluorenylmethyloxycarbonyl, and the claim also recites “preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 4 recites the broad recitation, R is a C1-C6 alkyl or benzyl, and the claim also recites, “preferably selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl”, which is the narrower statement of the range/limitation. Claim 4 also recites broad/narrow limitations of the palladium catalyst and the phosphine ligand. Claim 6 recites the broad recitation, R is a C1-C6 alkyl or benzyl, and the claim also recites, “preferably selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl”, which is the narrower statement of the range/limitation. Claim 6 also recites broad/narrow limitations for the acid used. Claim 9 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, an fluorenylmethyloxycarbonyl, and the claim also recites “preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation. Claim 9 also recites that “preferably” R is selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl. Claim 12 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, and fluorenylmethyloxycarbonyl, and the claim also recites “more preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation. Claims 14 and 15 are drawn to the use of the compound of formula V and the use of the compound of formula III for the preparation of compound I, campotothecins, and/or an antibody drug conjugate. However, the claims do not recite any positive method steps attributed to the production of compound I, thereby rendering the claims indefinite. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 14 and 15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because applicants claim the use of the compound of formula V and the use of the compound of formula III for the preparation of compound I, campotothecins, and/or an antibody drug conjugate. However, the claims do not recite any positive method steps attributed to the production of compound I. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: claims 1, 3, 5, 7, 8, 10, 11, and 13 are drawn to a process for producing 5,8-diamino-3,4-dihydro-2H-1-naphthalenone, and to intermediate compounds that are not or fairly suggested by prior art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SIKARL A WITHERSPOON whose telephone number is (571)272-0649. The examiner can normally be reached M-F 9am-9pm IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SIKARL A WITHERSPOON/ Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Feb 07, 2024
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780771
ORGANIC TERTIARY OR QUATERNARY AMMONIUM SALTS AS CATALYSTS IN THE FORMATION OF GAMMA, DELTA-UNSATURATED KETONES
3y 3m to grant Granted Nov 03, 2026
Patent 12780773
METHOD FOR REACTIVE METHYL ACETATE DISTILLATION
2y 6m to grant Granted Nov 03, 2026
Patent 12773404
USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS
2y 4m to grant Granted Oct 27, 2026
Patent 12767624
METHOD FOR PURIFYING CANNABINOID COMPOUNDS
3y 5m to grant Granted Oct 20, 2026
Patent 12767685
METHOD OF PREPARING ESTRADIOL DERIVATIVES BY SOLID-PHASE SYNTHESIS
3y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
86%
Grant Probability
66%
With Interview (-20.1%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1668 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month